Bli medlem
Bli medlem

Du är här

2016-10-17

PCI Biotech: Distribution of todays presentation at United European Gastroenterology Week

Oslo, October 17, 2016 - reference is made to the announced oral presentation
from the phase I bile duct cancer study as late-breaking news at the United
European Gastroenterology (UEG) Week. The presentation "Phase I study with
photochemical Internalisation (PCI) - a novel technology for treatment of
perihilar cholangiocarcinoma" by Dr. Alexander Dechêne, University Hospital
Essen, Germany, is attached.

About United European Gastroenterology (UEG)
United European Gastroenterology, is a professional non-profit organisation
combining all the leading European societies concerned with digestive health.
The member societies represent over 22,000 specialists, working across
medicine, surgery, paediatrics, GI oncology and endoscopy. This makes UEG the
most comprehensive organisation of its kind in the world, and a unique
platform for collaboration and the exchange of knowledge.

About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and
commercialisation of novel therapies for the treatment of cancer through its
innovative photochemical internalisation (PCI) technology platform. PCI is
applied to three distinct anticancer paradigms:fimaChem

(enhancement of chemotherapeutics for localised treatment of cancer),fimaVacc

(T-cell induction technology for therapeutic vaccination), andfimaNAc

(nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company's leadfimaChem

programme consists of a Phase I/II clinical study in bile duct cancer, an
orphan indication with a high unmet need and without approved
products.fimaVacc

applies a unique mode of action to enhance the essential cytotoxic effect of
therapeutic cancer vaccines, which works in synergy with several other
state-of-the-art vaccination technologies.fimaNAc

utilises the endosomal release to provide intracellular delivery of nucleic
acids, such as mRNA and siRNA therapeutics, thereby addressing one of the
major bottlenecks facing this emerging and promising field.

For more information visit: www.pcibiotech.com

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Ph I CCA presentation UEGW Oct 2016
http://hugin.info/139147/R/2049371/766385.pdf

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCI Biotech Holding via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.